Trial Profile
A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Sickle Cell Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Sep 2015
Price :
$35
*
At a glance
- Drugs HQK 1001 (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Sponsors HemaQuest Pharmaceuticals
- 21 Mar 2014 New trial record